ArticleAlzheimer's research & therapy2023
APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly.
Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 30 citations in OpenAlex.
- Genetic validation of ABI3 p.Ser209Phe variant and its effects on early brain pathology in asymptomatic elderly individuals.Alzheimer's research & therapy · 2026Article
- Clinical translation of fluid, imaging, and digital biomarkers for Alzheimer's disease.Alzheimer's research & therapy · 2026Review
- Neuroinflammation demonstrated byAlzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Longitudinal biomarker studies in human neuroimaging: capturing biological change of Alzheimer's pathology.Alzheimer's research & therapy · 2025Review
- Neuroprotective mechanisms of dexmedetomidine in perioperative neurocognitive disorders: From molecular pathways to clinical translation.Journal of anesthesia and translational medicine · 2025Review
- Interplay between astrocyte reactivity and APOE ε4 status is associated with accelerated pTau-related tau pathology in Alzheimer's disease.Molecular neurodegeneration · 2025Article
- Differential associations of APOE and TREM2 variants with glial fibrillary acidic protein and neurofilament light in plasma of UK Biobank participants support distinct disease mechanisms.Molecular psychiatry · 2025Article
- How to measure and model cardiovascular aging.Cardiovascular research · 2025Review
- Plasma phospho-tau217 as a predictive biomarker for Alzheimer's disease in a large south American cohort.Alzheimer's research & therapy · 2025Article
- A high-accuracy, low-cost blood test for Alzheimer's disease: validating P-tau181/Aβ42 in real-world cohorts.Frontiers in aging neuroscience · 2025Article
- Free-water imaging of the nucleus basalis of Meynert in apolipoprotein E4 carriers.Frontiers in aging neuroscience · 2025Article
- APOE4 Increases Susceptibility to Amyloid, Accelerating Episodic Memory Decline.bioRxiv : the preprint server for biology · 2024Article
- SV2A PET shows hippocampal synaptic loss in cognitively unimpaired APOE ε4/ε4 homozygotes.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Lower activity of cholesteryl ester transfer protein (CETP) and the risk of dementia: a Mendelian randomization analysis.Alzheimer's research & therapy · 2024Article
- APOE ε4 carrier status modifies plasma p-tau181 concentrations in cognitively healthy super-seniors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Matrix Remodeling Enzymes as Potential Fluid Biomarkers of Neurodegeneration in Alzheimer's Disease.International journal of molecular sciences · 2024Article
- Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly.Alzheimer's research & therapy · 2024Article
- APOE4 homozygozity represents a distinct genetic form of Alzheimer's disease.Nature medicine · 2024Article
- Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.Alzheimer's research & therapy · 2023Article
- Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 8 institutions in 5 countries.
Funding
Abstract
backgroundNeuroinflammation, characterized by increased reactivity of microglia and astrocytes in the brain, is known to be present at various stages of the Alzheimer's disease (AD) continuum. However, its presence and relationship with amyloid pathology in cognitively normal at-risk individuals is less clear. Here, we used positron emission tomography (PET) and blood biomarker measurements to examine differences in neuroinflammation and beta-amyloid (Aβ) and their association in cognitively unimpaired homozygotes, heterozygotes, or non-carriers of the APOE ε4 allele, the strongest genetic risk for sporadic AD.
methodsSixty 60-75-year-old APOE ε4 homozygotes (n = 19), heterozygotes (n = 21), and non-carriers (n = 20) were recruited in collaboration with the local Auria biobank. The participants underwent
resultsIn our cognitively unimpaired sample, cortical
conclusionsOnly Aβ burden measured by PET, but not markers of neuroinflammation, differed among cognitively unimpaired elderly with different APOE ε4 gene dose. However, APOE ε4 gene dose seemed to modulate the association between neuroinflammation and Aβ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.